For the quarter ending 2025-09-30, LGND made $115,461K in revenue. $117,273K in net income. Net profit margin of 101.57%.
| Income Statement | 2025-09-30 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Total revenues and other income | 115,461 | - | 51,812 | 41,531 |
| Cost of captisol | 3,801 | - | 2,449 | 2,906 |
| Amortization of intangibles | 8,097 | - | 8,258 | 8,257 |
| Research and development | 21,019 | - | 5,675 | 5,354 |
| General and administrative | 28,446 | - | 24,475 | 17,623 |
| Financial royalty assets impairment | 0 | - | - | 26,491 |
| Fair value adjustments to partner program derivatives | 833 | - | -7,812 | - |
| Total operating costs and expenses | 60,530 | - | 48,669 | 60,631 |
| Operating income (loss) | 54,931 | -3,324 | 3,143 | -19,100 |
| Gain (loss) from short-term investments | 7,798 | 43,437 | 2,407 | -14,256 |
| Gain (loss) from change in fair value of equity-method investments and other investments | 75,887 | - | - | - |
| Interest income | 3,874 | 1,976 | 1,347 | 2,757 |
| Interest expense | 910 | 514 | 741 | 1,268 |
| Other non-operating expense, net | -443 | -4,450 | -12,495 | -33,523 |
| Total non-operating income (expenses), net | 86,206 | 40,448 | -9,482 | -46,290 |
| Income (loss) before income taxes | 141,137 | 37,124 | -6,339 | -65,390 |
| Income tax expense | 23,864 | 9,598 | 833 | -13,479 |
| Net income (loss) from continuing operations | - | 27,526 | -7,172 | -51,911 |
| Net income (loss) | 117,273 | 27,526 | -7,172 | -51,911 |
| Basic net income (loss) per share (in usd per share) | 5.99 | 1.525 | -0.39 | -2.88 |
| Diluted net income (loss) per share (in usd per share) | 5.68 | 1.525 | -0.39 | -2.88 |
| Shares used in basic per share calculation (in shares) | 19,578,000 | -9,078,500 | 18,419,000 | 18,028,000 |
| Shares used in diluted per share calculation (in shares) | 20,629,000 | -9,078,500 | 18,419,000 | 18,028,000 |
LIGAND PHARMACEUTICALS INC (LGND)
LIGAND PHARMACEUTICALS INC (LGND)